Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 6 May 2020 |
| Orion Corporation: Decisions by the AGM on 6 May 2020 | 6 May 2020 |
| Orion Corporation: Managers’ transactions – Virve Laitinen | 30 Apr 2020 |
| Orion Corporation: Managers’ transactions – Satu Ahomäki | 29 Apr 2020 |
| Orion Corporation: Managers’ transactions – Liisa Hurme | 29 Apr 2020 |